Counting the cost of proton pump inhibitors

Gut

Volumn 49, Issue 4, 2001, Pages 462-463

  Moayyedi, P ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NOTE; PRIORITY JOURNAL;

ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0034829368     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.4.462     Document Type: Note

References (11)

1. Gastro-oesophageal reflux disease
2. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
3. The cost of long term therapy for gastro-oesophageal reflux disease: A randomised trial comparing omeprazole and open antireflux surgery
4. How to use an article on economic analysis of clinical practice
5. Long term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery
6. Handling uncertainty in economic evaluations of healthcare interventions
7. How should cost data in pragmatic randomised trials be analysed?
8. Estimating medical costs from incomplete follow-up data
9. Emerging issues in designing economic evaluations alongside clinical trials
10. Economic analysis alongside clinical trials. Revisting the methodological issues